uniQure NV(QURE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

QURE uniQure NV

Market Closed 10-09 16:00:00 EDT

22.59

+0.05

+0.22%

盘后22.59

+0.000.00%

19:32 EDT

High23.00	Low22.23	Vol2.05M
Open22.59	D1 Closing22.54	Amplitude3.42%
Mkt Cap1.57B	Tradable Cap1.30B	Total Shares69.37M
T/O46.29M	T/O Rate3.56%	Tradable Shares57.53M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"QURE","market":"US","secType":"STK","nameCN":"uniQure NV","latestPrice":22.59,"timestamp":1791576000000,"preClose":22.54,"halted":0,"volume":2049878,"hourTrading":{"tag":"盘后","latestPrice":22.59,"preClose":22.59,"latestTime":"19:32 EDT","volume":1098246,"amount":24809332.6875,"timestamp":1791588764132,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0022182786157941754,"floatShares":57525100,"shares":69366400,"eps":-4.039896,"marketStatus":"Market Closed","change":0.05,"latestTime":"10-09 16:00:00 EDT","open":22.59,"high":23,"low":22.23,"amount":46290154.357346006,"amplitude":0.034161,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.039896,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1391576400000,"exchange":"NASDAQ","adjPreClose":22.54,"preHourTrading":{"tag":"盘前","latestPrice":22.59,"preClose":22.54,"latestTime":"09:29 EDT","volume":719,"amount":16213.148019999999,"timestamp":1791552599999,"change":0.05,"changeRate":0.002218,"amplitude":0.017746},"postHourTrading":{"tag":"盘后","latestPrice":22.59,"preClose":22.59,"latestTime":"19:32 EDT","volume":1098246,"amount":24809332.6875,"timestamp":1791588764132,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.8978833047333795,"impliedVol":1.079,"impliedVolPercentile":0.4143},"requestUrl":"/m/hq/s/QURE","defaultTab":"news","newsList":[{"id":"2673067104","title":"Gene Therapy Data Could Be A Big Moment For uniQure Stock (QURE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2673067104","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673067104?lang=en_us&edition=fundamental","pubTime":"2026-10-07 10:22","pubTimestamp":1791339740,"startTime":"0","endTime":"0","summary":"uniQure reported new Phase I/II data for its Huntington’s disease gene therapy ifezuntirgene inilparvovec, showing continued slowing of disease progression at 36 and 48 months versus external controls, alongside a generally manageable safety profile.\nA key operational milestone is the FDA’s prior feedback that 36 month high dose data from 12 patients could underpin an accelerated approval BLA, which links these long term outcomes directly to uniQure’s near term regulatory path.\nWe will now...","market":"nz","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/gene-therapy-data-could-be-a-big-moment-for-uniqure-stock-qu","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/gene-therapy-data-could-be-a-big-moment-for-uniqure-stock-qu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0889565916.HKD","LU0320765992.SGD","QURE","BK4139","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673535081","title":"UniQure Shares Fall After Barclays Downgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2673535081","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673535081?lang=en_us&edition=fundamental","pubTime":"2026-10-06 03:40","pubTimestamp":1791229252,"startTime":"0","endTime":"0","summary":"UniQure (QURE) shares fell 3% in Monday trading after Barclays downgraded the stock to equal weight from overweight.Trading volume stood at about 2.3 million shares, compared with a daily average of over 1.9 million.Price: 22.77, Change: -0.70, Percent Change: -2.96","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LU0320765992.SGD","QURE","LU0109394709.USD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673700940","title":"uniQure Cut to Equal-Weight from Overweight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2673700940","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673700940?lang=en_us&edition=fundamental","pubTime":"2026-10-05 21:17","pubTimestamp":1791206220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/QURE/analyst-ratings","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","QURE","BK4139","LU0320765992.SGD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673313702","title":"Barclays Downgrades uniQure to Equal Weight From Overweight","url":"https://stock-news.laohu8.com/highlight/detail?id=2673313702","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673313702?lang=en_us&edition=fundamental","pubTime":"2026-10-05 19:45","pubTimestamp":1791200718,"startTime":"0","endTime":"0","summary":"uniQure (QURE) has an average rating of buy and mean price target of $63.73, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0889565916.HKD","LU0320765992.SGD","QURE","BK4139","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673777044","title":"Mendus Appoints Hans Preusting as COO","url":"https://stock-news.laohu8.com/highlight/detail?id=2673777044","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673777044?lang=en_us&edition=fundamental","pubTime":"2026-10-05 14:03","pubTimestamp":1791180205,"startTime":"0","endTime":"0","summary":"Mendus appoints Hans Preusting as COOMendus appointed Hans Preusting as chief operating officer, effective Oct. 5, 2026.Preusting will step down from the board, where he has served as an independent m","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nNDL8m4lJl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU0889565916.HKD","BK4139","QURE","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672711872","title":"RBC Cuts Price Target on uniQure to $48 From $65, Keeps Outperform, Speculative Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2672711872","media":"MT Newswires Live","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672711872?lang=en_us&edition=fundamental","pubTime":"2026-10-02 19:42","pubTimestamp":1790941350,"startTime":"0","endTime":"0","summary":"uniQure (QURE) has an average rating of buy and mean price target of $63.73, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0109394709.USD","QURE","BK4139","LU0320765992.SGD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672716511","title":"Uniqure N.v. : RBC Cuts Target Price to $48 from $65","url":"https://stock-news.laohu8.com/highlight/detail?id=2672716511","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672716511?lang=en_us&edition=fundamental","pubTime":"2026-10-02 18:30","pubTimestamp":1790937005,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nFWN45O0M0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0889565916.HKD","QURE","BK4139","LU0109394709.USD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671270479","title":"Barclays Sticks to Their Buy Rating for uniQure (QURE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2671270479","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671270479?lang=en_us&edition=fundamental","pubTime":"2026-09-30 17:25","pubTimestamp":1790760337,"startTime":"0","endTime":"0","summary":"In a report released today, Eliana Merle from Barclays maintained a Buy rating on uniQure, with a price target of $60.00. Merle covers the Healthca...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-sticks-to-their-buy-rating-for-uniqure-qure-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-sticks-to-their-buy-rating-for-uniqure-qure-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671244216","title":"uniQure weakness creates attractive opportunity, says Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2671244216","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671244216?lang=en_us&edition=fundamental","pubTime":"2026-09-30 03:15","pubTimestamp":1790709320,"startTime":"0","endTime":"0","summary":"Wells Fargo reiterated an Overweight rating and $75 price target on uniQure (QURE). New four-year data on UHDRS, a secondary endpoint that appears ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/uniqure-weakness-creates-attractive-opportunity-says-wells-fargo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/uniqure-weakness-creates-attractive-opportunity-says-wells-fargo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0072461881.USD","FTXO","LU1894683348.USD","LU0162691827.USD","IE0002270589.USD","IE00B19Z3B42.SGD","LU0267386448.USD","LU0130102774.USD","TFNS","PGF","LU0971096721.USD","BK4504","LU1668664300.SGD","LU1814569148.SGD","LU0640476718.USD","LU2236285917.USD","LU0208291251.USD","LU0708994859.HKD","BK4139","BK4585","LU1791807156.HKD","LU0130517989.USD","LU0683600562.USD","LU1280957306.USD","LU0320765992.SGD","LU2361044949.HKD","IYF","LU0175139822.USD","LU0310800379.SGD","BK4501","LU0889565916.HKD","LU0942090050.USD","LU0648001328.SGD","LU0048573561.USD","LU0211328371.USD","LU2361045086.USD","QURE","LU0787776722.HKD","LU0417517546.SGD","LU1201861249.SGD","BK4207","BK4588","LU1074936037.SGD","LU1267930573.SGD","LU0314106906.USD","KBWB","LU0256863811.USD","LU0320765489.SGD","LU0052756011.USD","LU0149725797.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671442682","title":"RBC says uniQure’s four-year HD data mixed, stock reaction ‘overdone’","url":"https://stock-news.laohu8.com/highlight/detail?id=2671442682","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671442682?lang=en_us&edition=fundamental","pubTime":"2026-09-30 03:00","pubTimestamp":1790708413,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Luca Issi notes the uniQure (QURE) updated three-year data and reported first look at the four-year data for Huntington’s disea...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rbc-says-uniqures-four-year-hd-data-mixed-stock-reaction-overdone-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rbc-says-uniqures-four-year-hd-data-mixed-stock-reaction-overdone-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029864427.USD","LU0109394709.USD","LU0708994859.HKD","LU0128525929.USD","LU0889565916.HKD","LU1267930573.SGD","QURE","LU0320765992.SGD","LU0310800379.SGD","GSIB","BK4207","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671497032","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2671497032","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671497032?lang=en_us&edition=fundamental","pubTime":"2026-09-30 01:46","pubTimestamp":1790703991,"startTime":"0","endTime":"0","summary":"UniQure  shares were down more than 38% after the company reported additional data from its ongoing phase 1/2 studies of AMT-130 in Huntington's disease that showed less pronounced benefits at 48 months.Intraday trading volume increased to over 23.7 million shares after midday Tuesday from the stock's daily average of under 1.4 million.Julong  shares fell over 32% after the company announced a private placement of shares and warrants.Trading volume was more than 814,000 shares compared with a daily average of about 2.9 million.Fair Isaac  shares tumbled nearly 27% after Federal Housing Finance Agency Director Bill Pulte said late Monday on X that VantageScore will join the existing FICO classic mortgage pricing grid.More than 3.5 million shares traded intraday, compared with a daily average of about 351,000.Price: 24.20, Change: -14.91, Percent Change: -38.12","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","LU0289739343.SGD","LU2360106780.USD","LU0472753341.HKD","LU0057025933.USD","LU0320765992.SGD","IE00BLDYK493.USD","BK4139","LU2087625088.SGD","LU2250418816.HKD","BK4023","LU0289961442.SGD","FDIQ","BK4585","LU0353189763.USD","BK4129","LU0353189680.USD","LU0889565916.HKD","LU0069063385.USD","LU0056508442.USD","BK4608","JLHL","IE00B64QTZ34.USD","LU0511384066.AUD","FICO","QURE","LU0109394709.USD","LU1852331112.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671246203","title":"uniQure ‘mixed’ four-year data complicates durability case, says H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2671246203","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671246203?lang=en_us&edition=fundamental","pubTime":"2026-09-30 00:46","pubTimestamp":1790700364,"startTime":"0","endTime":"0","summary":"After uniQure (QURE) announced additional data from the ongoing Phase I/II studies of ifezuntirgene inilparvovec for the treatment of Huntington’s ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/uniqure-mixed-four-year-data-complicates-durability-case-says-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/uniqure-mixed-four-year-data-complicates-durability-case-says-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0889565916.HKD","QURE","BK4139","LU0320765992.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671246823","title":"France's MaaT Pharma H1 Operating Loss Widens on Higher R&D Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2671246823","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671246823?lang=en_us&edition=fundamental","pubTime":"2026-09-30 00:17","pubTimestamp":1790698623,"startTime":"0","endTime":"0","summary":"France's MaaT Pharma H1 operating loss widens on higher R&D costsOverviewFrance biotech firm's H1 2026 revenue fell 55% yr/yr due to EAP model changesOperating loss widened to EUR 18.3 mln as R&D spen","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nL1N45L0PU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","BK4139","QURE","LU0320765992.SGD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671246343","title":"uniQure falls -38.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2671246343","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671246343?lang=en_us&edition=fundamental","pubTime":"2026-09-30 00:06","pubTimestamp":1790697996,"startTime":"0","endTime":"0","summary":"uniQure (QURE) is down -38.4%, or -$15.01 to $24.10. Published first on TheFly – the ultimate source for real-time, market-moving breaking financia...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/uniqure-falls-38-4-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/uniqure-falls-38-4-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0109394709.USD","BK4139","LU0889565916.HKD","LU0320765992.SGD","QURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671424541","title":"Crude Oil Down 1%; US Job Openings Fall In August","url":"https://stock-news.laohu8.com/highlight/detail?id=2671424541","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671424541?lang=en_us&edition=fundamental","pubTime":"2026-09-30 00:01","pubTimestamp":1790697669,"startTime":"0","endTime":"0","summary":"U.S. stocks fell as job openings declined; oil slid and gold rose. BKYI doubled, SSTI surged, while NIVF plunged 77% and QURE fell 37%.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/market-summary/26/09/62056184/crude-oil-down-1-us-job-openings-fall-in-august","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QQQE","TQQY","BKYI","SSTI","QQQA","IE00B19Z4B17.USD","ONEQ","QYLG","NDX","PSQ","MNQmain","QQQY","SQQQ","QQQ","IOVA","IE00B66KJ199.SGD","JEPQ","QDTE","QLD","TQQQ","LU0109394709.USD","AIR","BK4097","TECS","NIVF","BK4572","BK4187","FTEC","03086","IYW","QQQM","NQmain","NVIW.SI","BK4196","LU0889565916.HKD","IE00B7SZL793.SGD","QURE","QID","BK4023","GPIQ","LU0320765992.SGD","BK4139","QQQJ","IE0031619046.USD",".IXIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671245927","title":"U.S. Stocks on the MOVE-Snowflake, Cboe, Oracle","url":"https://stock-news.laohu8.com/highlight/detail?id=2671245927","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671245927?lang=en_us&edition=fundamental","pubTime":"2026-09-29 23:53","pubTimestamp":1790697222,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Snowflake, Cboe, OracleSept 29 (Reuters)-The benchmark S&P 500 was flat on Tuesday, as rising government bond yields hurt risk sentiment and offset gains in AI-related sto","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nL6N45L0Z6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMAT","ORCS","PLUG","CABO","VOR","UPGR","DAPP","STAA","SORCLmain","AIR","XDAT","WRBY","FCEL","CCL","QURE","EFX","PIPR","CVNX","FBT","EGGY","09311","VCYT","FNMA","ORCL","CVNY","WLK","SNOY","DXST","SSTI","URI","COIN","SNOW","VVV","WBD","ZAP","BLMN","KMX","CVNA","GRML","COYY","FICO","CLIX","FTCI","PWP","BKCH","PEP","GLW","T","BE","FMCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671210730","title":"Dow Tumbles 100 Points; Carnival Posts Upbeat Q3 Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2671210730","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671210730?lang=en_us&edition=fundamental","pubTime":"2026-09-29 22:13","pubTimestamp":1790691212,"startTime":"0","endTime":"0","summary":"U.S. stocks were mixed; Dow and S&amp;P 500 fell while Nasdaq edged up. Carnival beat estimates. BIO-Key surged 127%; oil dropped 2%.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/market-summary/26/09/62051438/dow-tumbles-100-points-carnival-posts-upbeat-q3-earnings","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QQQJ","QQQE","TECS","SQQQ","BK4585","NQmain","QDTE","NVIW.SI","TQQQ","QYLG","BK4023","BK4129","BK4142","BK4547","QQQY","SSTI","03086","QID","BKYI","ONEQ","PSQ","BK4184","BK4588","FTEC","LU0889565916.HKD","QURE","LU0320765992.SGD","ILLR","SLND","MNQmain","QLD","QQQ","QQQA","TQQY","JEPQ","LU0109394709.USD","CCL","IYW","BK4097","BK4517","NIVF","BK4196","QQQM","GPIQ",".IXIC","NDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671176842","title":"Sector Update: Healthcare Stocks Advance Pre-Bell Tuesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2671176842","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671176842?lang=en_us&edition=fundamental","pubTime":"2026-09-29 21:24","pubTimestamp":1790688276,"startTime":"0","endTime":"0","summary":"Healthcare stocks were advancing pre-bell Tuesday, with the State Street Health Care Select Sector SPDR ETF  up 0.1% and the iShares Biotechnology ETF  0.3% higher.Iovance Biotherapeutics  stock was up more than 18% after the company raised its full year 2026 total revenue guidance to a range of $410 million to $420 million, from its prior outlook of $350 million to $370 million.UniQure  shares were down more than 47% after the company said additional data from its ongoing phase 1/2 studies of AMT-130 in Huntington's disease showed less pronounced benefits at 48 months.Pharming Group  has appointed chief commercial officer Leverne Marsh and chief financial officer Kenneth Lynard as interim co-chief executive officers, the company said. Pharming Group stock was down more than 3% pre-bell.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0109394709.USD","LU0029874061.USD","BK4137","LABU","LU0320765992.SGD","IOVA","BK4585","LU0889565916.HKD","QURE","XLV","BK4139","PHAR","LU0128526141.USD","BK4581","HCSG","IBB","BK4588","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671121783","title":"UniQure Stock Drops After Huntington's Drug Results Disappoint at 4-Year Mark","url":"https://stock-news.laohu8.com/highlight/detail?id=2671121783","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671121783?lang=en_us&edition=fundamental","pubTime":"2026-09-29 21:12","pubTimestamp":1790687520,"startTime":"0","endTime":"0","summary":"Shares of uniQure slid after patients treated with its Huntington's disease drug in a recent study no longer showed a statistically significant slowdown in disease-induced decline after four years.The stock fell 47% to $20.91 in premarket trading on Tuesday. As of Monday's market close, shares were up 63% year to date.At four years, the study's primary endpoint--composite Unified Huntington's Disease Rating Scale --showed a 44% slowing of disease progression compared with an external control, but the data did not reach statistical significance, the company said.cUHDRS had shown 80% slowing of disease progression compared with the external control, with statistical significance, at three years.The latest study results draw from data on 12 high-dose patients. The company said the treatment effect could be understated by substantial missing data and survivor bias in an updated external control.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"UniQure Stock Drops After Huntington's Drug Results Disappoint at 4-Year Mark","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU0889565916.HKD","QURE","LU0109394709.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671348214","title":"UniQure Says Additional AMT-130 Data Show Weaker Results at 4 Years; Shares Tumble","url":"https://stock-news.laohu8.com/highlight/detail?id=2671348214","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671348214?lang=en_us&edition=fundamental","pubTime":"2026-09-29 20:26","pubTimestamp":1790684805,"startTime":"0","endTime":"0","summary":"UniQure  said Tuesday additional data from its ongoing phase 1/2 studies of AMT-130 in Huntington's disease showed less pronounced benefits at 48 months.The company said the primary endpoint of composite Unified Huntington's Disease Rating Scale showed 44% slowing of disease progression in 12 high-dose patients at 48 months, lower than the updated 36-month data of 80% slowing of disease progression in 15 high-dose patients.Total functional capacity delivered a 61% slowing of disease progression in 12 high-dose patients at 48 months, compared with the updated 36-month data of 67%, the company said.The company's shares fell 52.5% in premarket activity Tuesday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["WTRE","BYRE","PSR","BK4534","QURE","LU0320765992.SGD","ICF","URE","BK4084","FREL","TRUR","XLRE","HELS","DFGR","BK4581","REAI","DTRE","BK4219","DTCR","BK4585","BK4139","BK4588","LU0889565916.HKD","BK4554","IDGT","LU0109394709.USD","AVRE","AMT","VNQ","SRVR","CRED"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.uniqure.com","stockEarnings":[{"period":"1week","weight":-0.0371},{"period":"1month","weight":-0.5089},{"period":"3month","weight":-0.4701},{"period":"6month","weight":0.4688},{"period":"1year","weight":-0.6451},{"period":"ytd","weight":-0.056}],"compareEarnings":[{"period":"1week","weight":0.0116},{"period":"1month","weight":0.0212},{"period":"3month","weight":0.0313},{"period":"6month","weight":0.1459},{"period":"1year","weight":0.16},{"period":"ytd","weight":0.1417}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.009035},{"month":2,"riseRate":0.5,"avgChangeRate":0.032875},{"month":3,"riseRate":0.307692,"avgChangeRate":-0.046417},{"month":4,"riseRate":0.461538,"avgChangeRate":0.033828},{"month":5,"riseRate":0.692308,"avgChangeRate":0.072742},{"month":6,"riseRate":0.461538,"avgChangeRate":0.038554},{"month":7,"riseRate":0.230769,"avgChangeRate":0.026458},{"month":8,"riseRate":0.538462,"avgChangeRate":0.014427},{"month":9,"riseRate":0.230769,"avgChangeRate":0.07452},{"month":10,"riseRate":0.461538,"avgChangeRate":0.05075},{"month":11,"riseRate":0.75,"avgChangeRate":0.0616},{"month":12,"riseRate":0.25,"avgChangeRate":0.125134}],"exchange":"NASDAQ","name":"uniQure NV","nameEN":"uniQure NV"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"uniQure NV(QURE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest uniQure NV(QURE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"uniQure NV,QURE,uniQure NV股票,uniQure NV股票老虎,uniQure NV股票老虎国际,uniQure NV行情,uniQure NV股票行情,uniQure NV股价,uniQure NV股市,uniQure NV股票价格,uniQure NV股票交易,uniQure NV股票购买,uniQure NV股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"uniQure NV(QURE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest uniQure NV(QURE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}